121 related articles for article (PubMed ID: 11070840)
1. Monitoring of cellular resistance to cancer chemotherapy: drug retention and efflux.
Krishan A
Methods Cell Biol; 2001; 64():193-209. PubMed ID: 11070840
[No Abstract] [Full Text] [Related]
2. Flow cytometric monitoring of fluorescent drug retention and efflux.
Krishan A; Hamelik RM
Methods Mol Med; 2005; 111():149-66. PubMed ID: 15911978
[TBL] [Abstract][Full Text] [Related]
3. Rapid determination of cellular resistance-related drug efflux in tumor cells.
Krishan A
Methods Cell Biol; 1990; 33():491-500. PubMed ID: 2084481
[No Abstract] [Full Text] [Related]
4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
Xu HB; Li L; Liu GQ
Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
[TBL] [Abstract][Full Text] [Related]
5. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
[TBL] [Abstract][Full Text] [Related]
6. Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells.
Ferreira MJ; Duarte N; Gyémánt N; Radics R; Cherepnev G; Varga A; Molnár J
Anticancer Res; 2006; 26(5A):3541-6. PubMed ID: 17094479
[TBL] [Abstract][Full Text] [Related]
7. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia.
Schröder JK; Kasimir-Bauer S; Seeber S; Scheulen ME
J Cancer Res Clin Oncol; 2000 Feb; 126(2):111-6. PubMed ID: 10664252
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):281-4. PubMed ID: 11031728
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia.
Tsimberidou AM; Paterakis G; Androutsos G; Anagnostopoulos N; Galanopoulos A; Kalmantis T; Meletis J; Rombos Y; Sagriotis A; Symeonidis A; Tiniakou M; Zoumbos N; Yataganas X
Leuk Res; 2002 Feb; 26(2):143-54. PubMed ID: 11755464
[TBL] [Abstract][Full Text] [Related]
10. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
[TBL] [Abstract][Full Text] [Related]
11. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
12. Rho(0) tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin, and other drugs.
Hu Y; Moraes CT; Savaraj N; Priebe W; Lampidis TJ
Biochem Pharmacol; 2000 Dec; 60(12):1897-905. PubMed ID: 11108806
[TBL] [Abstract][Full Text] [Related]
13. Dyes providing increased sensitivity in flow-cytometric dye-efflux assays for multidrug resistance.
Frey T; Yue S; Haugland RP
Cytometry; 1995 Jul; 20(3):218-27. PubMed ID: 7587707
[TBL] [Abstract][Full Text] [Related]
14. Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Vanhuyse M; Kluza J; Tardy C; Otero G; Cuevas C; Bailly C; Lansiaux A
Cancer Lett; 2005 Apr; 221(2):165-75. PubMed ID: 15808402
[TBL] [Abstract][Full Text] [Related]
15. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells.
Nagasawa K; Natazuka T; Chihara K; Kitazawa F; Tsumura A; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Cancer Chemother Pharmacol; 1996; 37(4):297-304. PubMed ID: 8548874
[TBL] [Abstract][Full Text] [Related]
16. The ability of verapamil to restore intracellular accumulation of anthracyclines in multidrug resistant cells depends on the kinetics of their uptake.
Mankhetkorn S; Garnier-Suillerot A
Eur J Pharmacol; 1998 Feb; 343(2-3):313-21. PubMed ID: 9570481
[TBL] [Abstract][Full Text] [Related]
17. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T
Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640
[TBL] [Abstract][Full Text] [Related]
18. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
Lehne G; De Angelis P; Clausen OP; Rugstad HE
Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
[TBL] [Abstract][Full Text] [Related]
19. In vitro flow cytometry method to quantitatively assess inhibitors of P-glycoprotein.
Wang EJ; Casciano CN; Clement RP; Johnson WW
Drug Metab Dispos; 2000 May; 28(5):522-8. PubMed ID: 10772630
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
